How to Lose Visceral Fat: Mechanisms of Central Obesity
Not especially heavy overall, yet the belly is round, the waist is over the limit, and checkups flag fatty liver — this is central obesity: visceral fat is making itself heard.
Visceral fat vs. subcutaneous fat
Section titled “Visceral fat vs. subcutaneous fat”| Subcutaneous fat | Visceral fat | |
|---|---|---|
| Location | Pinchable, under the skin | Inside the abdominal cavity, wrapping the organs |
| Metabolism | Relatively inert | Actively broken down; free fatty acids reach the liver |
| Risk | Low | Insulin resistance, inflammation, cardiovascular |
| Difficulty to lose | Stubborn but responsive to a calorie deficit | Sensitive to hormones and diet composition |
Visceral fat cells have more sensitive adrenergic receptors, yet cortisol, insulin, and the testosterone-to-estrogen ratio all affect how it accumulates.
Why belly fat is so hard to lose
Section titled “Why belly fat is so hard to lose”- Cortisol: under chronic stress, fat is preferentially distributed to the viscera.
- Insulin resistance: high insulin promotes fat storage, especially abdominal.
- Insufficient sleep: leptin ↓ ghrelin ↑, late-night snacking urges.
- Fruit wine and refined carbohydrates: fructose metabolism and alcohol metabolism both favor liver fat.
- Age and hormones: fat redistributes after midlife.
Solutions to common problems
Section titled “Solutions to common problems”- Adequate protein, fewer refined carbs, less alcohol.
- Dietary fiber (soluble) improves insulin sensitivity.
- Don’t crash-diet: it costs muscle and raises cortisol.
Exercise
Section titled “Exercise”- Resistance training + HIIT/cardio: the evidence for visceral fat is relatively good.
- Step count: NEAT offsets the harms of sitting.
Sleep and stress
Section titled “Sleep and stress”- 7–9 hours of sleep is the hidden condition for losing visceral fat.
- Breathing exercises, walking, and strength training lower cortisol.
Research and drug interventions for visceral fat
Section titled “Research and drug interventions for visceral fat”Tesamorelin
Section titled “Tesamorelin”A GHRH analog with a history of indication research/approval for HIV-associated visceral fat gain — the most mature example in targeted visceral-fat reduction research.
GH secretagogue route
Section titled “GH secretagogue route”Ipamorelin, CJC-1295, and similar compounds relate to growth-hormone pulsatility and theoretically affect body composition; they appear mostly in research and have not yet been written into mainstream weight-loss guidelines.
GLP-1 / dual agonists
Section titled “GLP-1 / dual agonists”When weight loss is substantial, visceral fat reduction is usually significant; improvement in fatty liver is followed closely in studies of Tirzepatide, Retatrutide, and others.
MOTS-c and exercise-mimetic peptides
Section titled “MOTS-c and exercise-mimetic peptides”AMPK, glucose uptake — metabolic-phenotype discussion.
Waist circumference is worth watching more than weight
Section titled “Waist circumference is worth watching more than weight”A waist circumference of ≥90 cm in men and ≥85 cm in women (Chinese standard) is a simple warning line for visceral-fat risk. Measuring the waist is more useful than stepping on the scale every day.
Subcutaneous fat vs. visceral fat
Section titled “Subcutaneous fat vs. visceral fat”| Subcutaneous | Visceral | |
|---|---|---|
| Location | Pinchable | Abdominal cavity, wraps organs |
| Metabolism | More inert | Free fatty acids to the liver |
| Risk | Relatively low | Insulin resistance, cardiovascular |
| Hormone response | Less sensitive | More sensitive to cortisol, insulin |
Intervention priorities
Section titled “Intervention priorities”- Control alcohol and fructose.
- Resistance training + HIIT (stronger evidence for visceral fat).
- Protein 1.6–2.2 g/kg.
- Sleep 7–9 hours, stress management.
- Drug/peptide tools (see the GLP-1 and Tesamorelin sections).
Related ingredients and mechanisms
Section titled “Related ingredients and mechanisms”- Tesamorelin: the most substantial visceral-fat research.
- Tirzepatide, Retatrutide: metabolic pathways.
- Blends: TSM10IPA5, TR30CAG5.
- Mechanisms: GLP-1 Drugs.
Methods and metrics
Section titled “Methods and metrics”Visceral fat is commonly measured by CT/MRI area, waist circumference, and waist-to-hip ratio; liver fat can be assessed with MRI-PDFF. Tesamorelin trials used CT visceral-fat area as the primary endpoint (PMID: 25038357).
Practical use and quality control
Section titled “Practical use and quality control”Before using or cross-checking any ingredient, review:
- Lyophilized Powder Reconstitution & Dose Conversion — BAC water, concentration, and IU scaling
- Storage, Cold Chain & Degradation — storage before and after reconstitution
- How to Read a COA / HPLC / MS — purity, content, salt form
- Routes of Administration & Bioavailability — subcutaneous, intranasal, oral, transdermal
Related reading
Section titled “Related reading”Further reading: Plateau, Insulin resistance, GLP-1 mechanisms, Metabolism-related peptides
Tesamorelin evidence on visceral fat
Section titled “Tesamorelin evidence on visceral fat”| Reference | Type | Key point |
|---|---|---|
| Tesamorelin and visceral/liver fat (PMID: 25038357) | RCT | Targets visceral fat; liver-fat endpoints |
| Fat “quality” improvement (PMID: 33756511) | Secondary analysis | Fat “quality” independent of quantity |
| Long-term safety/body composition (PMID: 41545261) | Clinical | HIV-associated lipodystrophy |
Key references
Section titled “Key references”Tesamorelin: PMID: 25038357, 41545261; body composition review PMID: 41076575.